Peter Braun is an accomplished, entrepreneurial, commercially and strategically astute leader with more than 25 years of experience in building businesses and delivering strong, sustainable results across the pharmaceutical and healthcare value chain. Previously, he held leadership positions in the biotechnology and biopharmaceutical industry and served as a strategic advisor to several emerging companies. Prior to that, Peter Braun had a long and successful career at Roche with senior leadership roles such as Lifecycle Leader for Herceptin, Country Head and most recently as Global Head of Access Strategy…

Christoph Rentsch is an expert in private and public funding markets and an executive corporate finance leader with more than 25 years of experience in the life science field. He started his career in investment banking and worked in senior management functions for the Alusuisse-Lonza Group both in Switzerland and in the USA. In 1994 he returned to Switzerland to join Roche as Head Group Funding and Capital Markets, taking responsibility for worldwide finance transactions. In 2004 he became managing partner of Caperis Ltd, a life science investment management firm…

Dr. Esteban Pombo-Villar has over 30 years of experience in biopharmaceutical R&D and business development leadership. Prior to joining TargImmune, he was Chief Operations Officer (COO) at Oxford BioTherapeutics. Prior to that, Dr. Pombo-Villar spent over 23 years at Novartis and Sandoz, the last 12 years in Business Development and Alliance Management and as Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR). Dr. Pombo-Villar earned a PhD, MSc and BSc in organic chemistry from the University of Warwick (UK) and was a visiting researcher at the University of Newcastle upon Tyne (UK)…

Dr. Maya Zigler has played a major role in the establishment of TargImmune and its activities. Dr Zigler completed her Ph.D at M.D. Anderson Cancer Center, Houston, Texas on melanoma metastases and progression. She has significant expertise and specialized knowledge in cancer biology. Dr. Zigler joined Professor Alex Levitzki’s laboratory as a postdoc in 2011 where she conducted extensive research, focused on expanding and improving the CTPIC technology to target additional cancer targets. She secured the ERC POC grant in 2013 for the Levitzki laboratory to pursue the CTPIC technology…

Catherine is an experienced executive and advisor who held various managerial roles (with focus in HR Management, organizational development, Compensation & Benefits and international contract law) in various international companies on local, regional and global level (Panalpina, Straumann). In 2013, Catherine decided to run her own HR Advisory company which is specialized in supporting Biotech companies in all HR related matters. From 2015 to 2019 she acted as Global Head Human Resources at Santhera Pharmaceuticals…

Kuno Sommer, Ph.D., today focuses on active board memberships in the life sciences sector as non-executive member. He became Chairman of the Board of the Bachem Group starting in 2012. In his last operational role he headed the contract research division of Harlan Laboratories Ltd. From 2000 until 2006 he was CEO of Berna Biotech Ltd, which was sold to Crucell N.V. in 2006 (today Johnson & Johnson). Starting in 1986 at F. Hoffmann-La Roche Ltd he worked in various functions until 1999 and spent 4 years in the US. In his last position at Roche he became a member of the Executive Committee…

Dr. Peter Kash is a co-founder and a lead investor in TargImmune Therapeutics. He is a global biotech entrepreneur and has raised significant capital for private biotech companies. He has co-founded and co-financed more than a dozen biotech companies. Collectively the companies he co-founded have 6 FDA approved drugs. Dr. Kash was a Adjunct Professor of Entrepreneurship at the Wharton School of Business and has been a Visiting Professor at several other leading universities including Hebrew University in Israel and Nihon University in Japan…

Professor of biochemistry at the Hebrew University of Jerusalem. Early in his career he earned his Ph.D. in (Biochemistry and Biophysics) Summa cum Laude at The Hebrew University in Jerusalem and The Weizmann Institute. Amongst many visiting professorships he also served as a Fogarty International Scholar at the National Institutes of Health, Bethesda, Maryland. Several of his outstanding honors include: The Israel Prize in Biochemistry (1990), the Rothschild Prize in Biology (1990), The Wolf Prize in Medicine (2005), The EMET Prize for Cancer Research (2017)…

Christoph Rentsch is an expert in private and public funding markets and an executive corporate finance leader with more than 25 years of experience in the life science field. He started his career in investment banking and worked in senior management functions for the Alusuisse-Lonza Group both in Switzerland and in the USA. In 1994 he returned to Switzerland to join Roche as Head Group Funding and Capital Markets, taking responsibility for worldwide finance transactions. In 2004 he became managing partner of Caperis Ltd, a life science investment management firm…

Mr. Fundarò has been with Genextra as chief financial officer first and then as Chief Executive officer since its inception in 2004. Mr. Fundarò has also served as a member of the board of directors of Genextra’s portfolio companies. In particular, he is currently Chairman of Intercept Pharmaceutical,Inc., Director of Innovheart and Erydel. In addition, Mr. Fundarò is also a founder and a Board Member of the Italian Angels for Biotech. Before joining Genextra, Mr. Fundarò was in charge of finance and strategic planning for Fastweb…

Dr. Alex Fässler has over 20 years of experience in operations management in the biopharmaceutical industry. He was previously Chief Operations Officer and member of the Corporate Executive Committee of Bachem, a leading service provider and CMO for peptides. Since 1998 he has held various management positions within the Bachem group, namely as Head of Production, Site Manager and finally COO of the US Organization. Alex Fässler started his industrial career as Medicinal Chemist at Ciba-Geigy, later Novartis, where he was engaged in drug discovery…

Dr. Andreas Wallnöfer is a board member of several European biotech companies and a senior executive leader with more than 20 years of experience in the pharmaceutical industry. He spent 12 years as a member of the F. Hoffmann-La Roche Pharma R&D Leadership and Portfolio Committee, and was Head of the Roche Pharma Cardiovascular & Metabolism Disease Area…